# Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

> **NCT01571284** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 781 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** AFLIBERCEPT AVE0005
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT01571284
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-30
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-01-31
- **Target enrollment:** 781 (ACTUAL)
- **Last updated:** 2018-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01571284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01571284, "Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01571284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*